ACADIA Pharmaceuticals Inc.

ACAD Healthcare Biotechnology

ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024.

Revenue
+22.9%
EPS
−27.9%
Free cash flow
+141.2%

Quarter to September 2026, against a year earlier

21.23 0.01 −0.05%
Market cap
$3.7B
P/E
10.0×
Fwd P/E
33.4×
Dividend yield
—
F-score
6/9
Altman Z
7.90
Beneish M
−0.89
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Piotroski F-Score
5 5 5 6

+8 more TTM periods

ROE
31.43% 35.74% 37.32% 39.89%
ROA
23.18% 25.64% 27.44% 28.42%
ROIC
18.60% 15.42% 12.75% 16.07%
Return on Tangible Assets
37.95% 43.23% 46.66% 49.34%
Average Days of Receivables
54.13 53.32 49.45 50.49
Free Cash Flow per Share
0.48 0.85 0.67 0.62
Free Cash Flow
81.99 145.63 113.59 104.69
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026